文献速递中枢神经肿瘤放疗

积极治疗对IDH野生型胶质母细胞瘤软脑膜播散患者结局的影响

Impact of Aggressive Treatment on Outcomes in IDH-Wildtype Glioblastoma Patients With Leptomeningeal Dissemination.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-09-27

这项多中心研究分析了2009年3月至2024年3月间5家机构的221例IDH野生型胶质母细胞瘤伴软脑膜播散患者,其中原发播散66例、复发播散155例。复发播散患者的总生存和无进展生存均显著差于原发播散者,且原发与复发播散患者的预后影响因素不同。在复发播散中,全面的放疗野覆盖和全身治疗与更好的生存相关。

要点

  • 复发播散者总生存(中位4.4 vs 12.1个月)和无进展生存(中位2.9 vs 6.7个月)均显著差于原发播散者。
  • 原发播散中,较好体能状态和较年轻与更长总生存相关,全切除与更好无进展生存相关。
  • 复发播散中,全面放疗野覆盖和全身治疗与总生存及无进展生存改善相关,贝伐珠单抗与非贝伐珠单抗方案生存获益相似。

核心结论

  • 原发与复发软脑膜播散的预后影响因素可能不同。
  • 在复发时发生软脑膜播散的IDH野生型胶质母细胞瘤患者中,积极干预包括全面放疗野覆盖和全身治疗可能改善部分患者结局。

研究设计与样本

  • 多中心回顾性研究,纳入2009年3月至2024年3月间5家机构的221例IDH野生型胶质母细胞瘤伴软脑膜播散患者,包括66例原发播散和155例复发播散。
  • 采用Cox回归模型识别总生存和无进展生存的预后因素。

主要发现

  • 基于可用影像,多数患者软脑膜播散局限于颅内(原发播散86.4%,复发播散78.7%)。
  • 复发播散患者总生存显著更差(中位4.4 vs 12.1个月;P < .001),无进展生存也显著更差(中位2.9 vs 6.7个月;P < .001)。
  • 原发播散中,较好体能状态和较年轻与更长总生存相关,全切除与更好无进展生存相关。
  • 复发播散中,男性、MGMT启动子甲基化、全面放疗野覆盖和全身治疗与总生存及无进展生存均相关,贝伐珠单抗与非贝伐珠单抗方案生存获益相似。

关键数值与推荐

  • 复发播散中位总生存4.4个月,原发播散12.1个月(P < .001)。
  • 复发播散中位无进展生存2.9个月,原发播散6.7个月(P < .001)。
  • 原发播散软脑膜播散局限于颅内者占86.4%,复发播散占78.7%。

临床怎么用

  • 对IDH野生型胶质母细胞瘤伴软脑膜播散患者,应区分原发与复发播散以评估预后。
  • 复发播散患者可考虑全面放疗野覆盖和全身治疗等积极干预,贝伐珠单抗与非贝伐珠单抗方案均可选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The prognosis of patients with IDH-wildtype glioblastoma (GBM) with leptomeningeal dissemination (LMD) is dismal, but prognostic factors and the optimal treatment strategy for LMD are still not clearly defined. This multi-institutional study aims to analyze clinical factors that affect the outcomes of GBM patients with LMD. METHODS AND MATERIALS: A total of 221 patients with IDH-wildtype GBM with LMD diagnosed between March 2009 and March 2024 at 5 institutions were analyzed, including 66 primary LMD and 155 recurrent LMD. Prognostic factors for overall survival (OS) and progression-free survival (PFS) were identified using a Cox regression model. RESULTS: LMD was confined to the intracranial compartment in most patients (primary LMD, 86.4%; recurrent LMD, 78.7%) based on available imaging. Patients with recurrent LMD had significantly worse OS (median 4.4 vs 12.1 months; P < .001) and PFS (median 2.9 vs 6.7 months; P < .001) compared with those with primary dissemination. Among patients with primary LMD, longer OS was associated with better performance status and younger age, whereas gross total resection was also associated with improved PFS. In the recurrent setting, male sex, O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, comprehensive radiation therapy field coverage, and administration of systemic therapy were associated with both OS and PFS, with bevacizumab and non-bevacizumab regimens showing similar survival benefit. CONCLUSIONS: Our findings suggest that the prognostic impact of clinical and treatment-related factors on outcomes may be different between primary and recurrent LMD. In particular, aggressive intervention, including comprehensive radiation therapy field coverage and systemic therapy, may improve outcomes in selected patients with IDH-wildtype GBM who develop LMD at recurrence.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Jeon SH, Kim N, Yoon HI, et al. Impact of Aggressive Treatment on Outcomes in IDH-Wildtype Glioblastoma Patients With Leptomeningeal Dissemination. Int J Radiat Oncol Biol Phys. 2026. PMID: 42801921. doi:10.1016/j.ijrobp.2026.09.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。